Novo-backed company strikes Big Pharma deal
A company from Novo Ventures’ portfolio have signed a significant licensing deal with one of the world’s biggest drug groups.
by Stefan Singh Kailay
US-based biotech Ophthotech, in which Novo Ventures is a major investor, has signed a licensing deal with swiss drug giant Novartis, the two parties announced this Monday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo-backed COPD company in rapid growth
For abonnenter
Novo kicks investments into next gear in 2014
For abonnenter
Novo heads capital injection in blood potassium company
For abonnenter
